265 related articles for article (PubMed ID: 32855362)
1. Coupled immune stratification and identification of therapeutic candidates in patients with lung adenocarcinoma.
Hu W; Wang G; Chen Y; Yarmus LB; Liu B; Wan Y
Aging (Albany NY); 2020 Aug; 12(16):16514-16538. PubMed ID: 32855362
[TBL] [Abstract][Full Text] [Related]
2.
Liu J; Han X; Chen L; Han D; Mu X; Hu X; Wu H; Wu H; Liu W; Zhao Y
Aging (Albany NY); 2020 Oct; 12(20):20308-20331. PubMed ID: 33091876
[TBL] [Abstract][Full Text] [Related]
3. Identification immunophenotyping of lung adenocarcinomas based on the tumor microenvironment.
Tan Q; Huang Y; Deng K; Lu M; Wang L; Rong Z; Zhao W; Li S; Xu Z; Fan L; Li K; Li Z
J Cell Biochem; 2020 Nov; 121(11):4569-4579. PubMed ID: 32030808
[TBL] [Abstract][Full Text] [Related]
4. A Novel Nucleic Acid Sensing-related Genes Signature for Predicting Immunotherapy Efficacy and Prognosis of Lung Adenocarcinoma.
Peng X; Wu H; Zhang B; Xu C; Lang J
Curr Cancer Drug Targets; 2024; 24(4):425-444. PubMed ID: 37592781
[TBL] [Abstract][Full Text] [Related]
5. Single-cell transcriptome analysis demonstrates inter-patient and intra-tumor heterogeneity in primary and metastatic lung adenocarcinoma.
Liu Y; Ye G; Huang L; Zhang C; Sheng Y; Wu B; Han L; Wu C; Dong B; Qi Y
Aging (Albany NY); 2020 Nov; 12(21):21559-21581. PubMed ID: 33170151
[TBL] [Abstract][Full Text] [Related]
6. Identification of a novel therapeutic candidate, NRK, in primary cancer-associated fibroblasts of lung adenocarcinoma microenvironment.
Wei T; Song J; Liang K; Li L; Mo X; Huang Z; Chen G; Mao N; Yang J
J Cancer Res Clin Oncol; 2021 Apr; 147(4):1049-1064. PubMed ID: 33387038
[TBL] [Abstract][Full Text] [Related]
7. Identification and validation of tumor environment phenotypes in lung adenocarcinoma by integrative genome-scale analysis.
Bi G; Chen Z; Yang X; Liang J; Hu Z; Bian Y; Sui Q; Li R; Zhan C; Fan H
Cancer Immunol Immunother; 2020 Jul; 69(7):1293-1305. PubMed ID: 32189030
[TBL] [Abstract][Full Text] [Related]
8. Identification of critical ferroptosis regulators in lung adenocarcinoma that RRM2 facilitates tumor immune infiltration by inhibiting ferroptotic death.
Tang B; Xu W; Wang Y; Zhu J; Wang H; Tu J; Weng Q; Kong C; Yang Y; Qiu R; Zhao Z; Xu M; Ji J
Clin Immunol; 2021 Nov; 232():108872. PubMed ID: 34648954
[TBL] [Abstract][Full Text] [Related]
9. Identification of immune-related gene signature predicting survival in the tumor microenvironment of lung adenocarcinoma.
Zhao M; Li M; Chen Z; Bian Y; Zheng Y; Hu Z; Liang J; Huang Y; Yin J; Zhan C; Feng M; Wang Q
Immunogenetics; 2020 Dec; 72(9-10):455-465. PubMed ID: 33188484
[TBL] [Abstract][Full Text] [Related]
10. A gene expression-based immune signature for lung adenocarcinoma prognosis.
Wang L; Luo X; Cheng C; Amos CI; Cai G; Xiao F
Cancer Immunol Immunother; 2020 Sep; 69(9):1881-1890. PubMed ID: 32372138
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level.
Wang W; Ren S; Wang Z; Zhang C; Huang J
Int Immunopharmacol; 2020 Jan; 78():106077. PubMed ID: 31812070
[TBL] [Abstract][Full Text] [Related]
12. Targeting Metabolic Bottlenecks in Lung Cancer.
Sayin VI; LeBoeuf SE; Papagiannakopoulos T
Trends Cancer; 2019 Aug; 5(8):457-459. PubMed ID: 31421901
[TBL] [Abstract][Full Text] [Related]
13. Immune subgroup analysis for non-small cell lung cancer may be a good choice for evaluating therapeutic efficacy and prognosis.
Tian Y; Wang J; Wen Q; Su G; Sun Y
Aging (Albany NY); 2021 May; 13(9):12691-12709. PubMed ID: 33973529
[TBL] [Abstract][Full Text] [Related]
14.
Liu L; Wang C; Li S; Qu Y; Xue P; Ma Z; Zhang X; Bai H; Wang J
Front Immunol; 2021; 12():677169. PubMed ID: 34354701
[TBL] [Abstract][Full Text] [Related]
15. Risk stratification for lung adenocarcinoma on EGFR and TP53 mutation status, chemotherapy, and PD-L1 immunotherapy.
Wu CH; Hwang MJ
Cancer Med; 2019 Oct; 8(13):5850-5861. PubMed ID: 31407494
[TBL] [Abstract][Full Text] [Related]
16. A signature of immune-related gene pairs predicts oncologic outcomes and response to immunotherapy in lung adenocarcinoma.
Xu F; Zhan X; Zheng X; Xu H; Li Y; Huang X; Lin L; Chen Y
Genomics; 2020 Nov; 112(6):4675-4683. PubMed ID: 32798715
[TBL] [Abstract][Full Text] [Related]
17. Integrated transcriptomics reveals master regulators of lung adenocarcinoma and novel repositioning of drug candidates.
De Bastiani MA; Klamt F
Cancer Med; 2019 Nov; 8(15):6717-6729. PubMed ID: 31503425
[TBL] [Abstract][Full Text] [Related]
18. Immune profile of the tumor microenvironment and the identification of a four-gene signature for lung adenocarcinoma.
Fan T; Zhu M; Wang L; Liu Y; Tian H; Zheng Y; Tan F; Sun N; Li C; He J
Aging (Albany NY); 2020 Dec; 13(2):2397-2417. PubMed ID: 33318300
[TBL] [Abstract][Full Text] [Related]
19. DNA methylation-based lung adenocarcinoma subtypes can predict prognosis, recurrence, and immunotherapeutic implications.
Xu F; He L; Zhan X; Chen J; Xu H; Huang X; Li Y; Zheng X; Lin L; Chen Y
Aging (Albany NY); 2020 Nov; 12(24):25275-25293. PubMed ID: 33234739
[TBL] [Abstract][Full Text] [Related]
20. Gene landscape and correlation between B-cell infiltration and programmed death ligand 1 expression in lung adenocarcinoma patients from The Cancer Genome Atlas data set.
Ho KH; Chang CJ; Huang TW; Shih CM; Liu AJ; Chen PH; Cheng KT; Chen KC
PLoS One; 2018; 13(12):e0208459. PubMed ID: 30521597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
